Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 29

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 29
---
 decide to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant to the Keystone Purchase Agreements. Accordingly, we cannot guarantee that we will be able to sell all of the Keystone Commitment Amount or how much in proceeds we may obtain under the Keystone Purchase Agreements. If we cannot sell securities under the Keystone Equity Financing, we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity and cash position. Because the purchase price per share of Common Stock to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the Keystone Purchase Agreements, if any, will fluctuate based on the market prices of our Common Stock at the time we make such election, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to Keystone under the Keystone Purchase Agreements, the purchase price per share that Keystone will pay for shares of Common Stock purchased from us under the Keystone Purchase Agreements, or the aggregate gross proceeds that we will receive from those purchases by Keystone under the Keystone Purchase Agreements. We previously registered an aggregate of 118,310 shares of our Common Stock on registration statement on Form S-1 (File No. 333-278603) and registration statement on Form S-1 (File No. 333-283492), which were declared effective by the SEC on May 1, 2024 and December 5, 2024, respectively, and remain in effect (the “Prior Registration Statements” and, together with the Current Registration Statement, the “Registration Statements”). Such shares consist of up to (i) 116,818 Keystone Purchase Shares that we may elect, in our sole discretion, to issue and sell to Keystone, from time to time under the Keystone Purchase Agreements, (ii) 992 Keystone Commitment Shares that have been issued to Keystone as consideration for its execution and delivery of the Keystone Purchase Agreements and (iii) up to 500 Arena Commitment Shares to be issued to Arena as consideration for its execution and delivery of the Arena Purchase Agreement. As of June 30, 2025, there were 1,194,802 shares of Common Stock outstanding and 2,126,003 shares of Common Stock outstanding on a fully-diluted basis. If all of the 12,500,000 shares